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Background: Currently the routine non-invasive screening methods for cervical intraepithelial neoplasia (CIN) and
cervical cancer are Thinprep cytology test (TCT) and human papillomavirus testing. However, both methods are
limited by the high false positive and false negative rates and lack of association with patients’ prognosis, especially
for the early detection of pro-malignant CIN. The aim of the study was to investigate the role of genomic
amplification of human telomerase gene (hTERC) in the diagnosis and prognosis of CIN.
Methods: The study group consisted of specimens of exfoliated cervical cells from 151 patients, including 27 with
CIN I, 54 with CIN II/III, 17 with carcinoma in situ, and 28 with invasive squamous carcinoma, as well as 25 patients
who were at 2-year follow-up after either Loop Electrosurgical Excision treatment (n = 11) or radical surgery (n = 14).
hTERC amplification was detected by dual-color interphase fluorescence in situ hybridization (FISH), and the results
were compared with TCT and histologic examination. The final diagnosis was determined by the pathological
examination. The control group consisted of specimens of exfoliated cervical cells from 40 normal women.
Results: The percentage of cervical exfoliated cells with positive hTERC amplification and incidence rates of hTERC
amplification were 9.2% ± 4.6% and 44.4% (12/27) respectively in patients with CIN I; 16.0% ± 14.4% and 85.1% (46/54)
in patients with CIN II/III; 19.7% ± 13.3% and 88.3% (15 /17) in patients with carcinoma in situ; 47.0% ± 25.2% and 100%
(28/28)in patients with invasive squamous carcinoma. There was statistically significant difference between the control
and study group (P <0.01), and between the patients with various diseases within the study group (P <0.05).
Conclusion: The detection of genomic amplification of hTERC using FISH is a non-invasive and effective
approach for CIN.
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Studies have shown that the incidence of cervical cancer
is closely associated with human papillomavirus (HPV)
infection, with HPV16 and HPV18 being the most com-
mon subtypes [1-3]. Currently routine non-invasive
screening methods for cervical intraepithelial neoplasia
(CIN) and cervical cancer are Thinprep cytology test
(TCT) and HPV testing. However, both methods are
limited by the high false positive and false negative rates* Correspondence: ygpwylll@hotmail.com
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reproduction in any medium, provided the orand lack of association with patients’ prognoses [4].
Therefore, exploring new non-invasive tests to assist the
diagnosis of cervical lesions, especially the early detec-
tion of pro-malignant CIN, is important in improving
the diagnosis and treatment of cervical cancer [5].
In recent years, studies have found that the overexpres-
sion of human chromosome telomerase gene (hTERC) is a
biological marker for cervical cancer [6]. Fluorescence in
situ hybridization (FISH) can be used to study the
chromosome of cervical cells or examine intra-cellular
genetic information within cells, and has been applied in
the diagnosis of cervical cancer [7,8]. Currently the main. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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electrical excision procedure (LEEP) [9], but the risk of
canceration still exits after treatment, especially for
patients with CIN II to III who were previously infected
with HPV, and long-term follow-up is usually necessary
[10-14]. In this study, FISH was used to detect hTERC
amplification before surgery in cervical exfoliated cells of
patients with CIN, and the results were compared with
normal cervical epithelium and exfoliated cells of patients
with cervical cancer. A retrospective analysis of patients
with CIN who reached 24-month post-operative follow-up
was also performed to assess the value of using hTERC
amplification in the clinical diagnosis and prognosis of
CIN. To the best of our knowledge, this is the first study
on this interesting issue.
Methods
Study population
Inclusion criteria: cervical cell specimens prior to treat-
ment were collected from patients who visited the
gynecology clinic at Jinan Military General Hospital
from December 2007 to December 2009. All patients
undertook cytological examination, colposcopy-directed
cervical biopsy [15,16], and received the LEEP or sur-
gery. The study sample comprised exfoliated cervical cell
specimens from 151 patients (average age 43.5 ± 8.5 years.
Mean ± SD), including 81 cases of CIN (27 grade I, 54
grade II to III, average age 38.5 ± 2.7 years) and 45 cases of
cervical squamous cell carcinoma (17 carcinoma in situ,
28 invasive carcinoma, average age 47.3 ± 13.5 years).
There were also 25 cervical cell smears collected from
patients who were followed for two years after treatment,
including 11 patients with CIN III treated by the LEEP
(average age 39.0 ± 4.5 years), and 14 patients with
squamous cervical carcinoma who received radical hys-
terectomy (average age 48.5 ± 10.5 years). All patients
provided informed consent to the use of their cervical
cell specimens in this study. This research was also
approved by the institutional review board prior to ini-
tiation. The control group included exfoliated cervical
cell specimens from 40 women who were healthy and
normal from routine gynecologic examination (negative
for intraepithelial lesion or malignancy (NILM) from
TCT, average age 41.7 ± 8.1 years). All cases were
confirmed by pathological examination.
Methods
For the collection of cervical cell specimens, a TCT spe-
cimen brush was inserted 2 to 3 cm into the cervical
canal, and rotated 5 times around the axis of the canal.
The cervical brush was kept in the TCT preservation so-
lution. Slides were made using the TCT smearing slide
machine, and Papanicolaou-stained. The remaining cellswere stored at 4 K for hTERC amplification detection
using FISH. The slides were processed twice (5 minutes
each time) with a 2-fold dilution of sodium citrate buffer
(SSC), with 0.1 mol/L hydrochloric acid solution for
10 minutes, with pepsin hydrochloric acid solution at
37 K for 8 minutes, 2-fold dilution of SSC twice more
(5 minutes each), 70%, 85%, 100% gradient ethanol solu-
tion at room temperature for 3 minutes each, and then
heated at 56 K for 3 minutes.
Dual color site-specific chromosome /centromeric
probes (hTERC/CSP3 DNA) were provided by GP Med-
ical Technologies Inc. (Beijing, China). CSP3 was used
as control probe. The hybridization of the hTERC DNA
probe with the chromosome 3 3q 26.3 would show a red
fluorescence signal and the hybridization of CSP3 DNA
with the centromere of chromosome 3 (3p11.1-q11.1)
would show a green fluorescence signal. For genetic
variability and hybridization, 70% formamide/2 × SSC
denaturation solution was pre-heated in warm water
(73 K), and the probing mixture was then added for
5 minutes, followed by 70%, 85%, 100% ethanol gradient
at −20 K. for 3 minutes each. Then 10 μL denatured
probing mixture was added to the hybridization area of
the slide, which was then covered and embedded in
mounting medium, incubated at 42 K overnight. On the
next day, the slides were placed in three bottles of for-
mamide washing solution at 46 K for 10 minutes each.
The coverslip was removed in the first bottle, and slides
were washed in the second and third bottle. Then the
slides were placed in 2 × SSC (B solution) at 46 K for
10 minutes, air dried in the dark, then read under a
fluorescent microscope after staining.
A threshold for positive cervical intraepithelial hTERC
amplification using FISH was established. The interphase
cell fluorescence hybridization signal was observed under
three-color fluorescence microscopy. Image analysis was
performed using fluorescence in situ hybridization ana-
lysis software (GP Medical Technologies Inc.) to evaluate
the hybridization of hTERC and CSP3 on the smear. For
the control group, based on the results of FISH test, the
percentage of cells with positive hTERC amplification
was defined as the percentage of cells with more than
two red fluorescent signals. The mean and SD was then
calculated for the control group according to the follow-
ing formula:
For the study group, a positive test was defined as the
percentage of cells with more than two red signals
higher than the positive threshold, indicating abnormal
hTERC amplification. If the percentage was lower than
the positive threshold, then the test was negative, indi-
cating normal hTERC amplification. If the percentage
was equal to the positive threshold, the result was reas-
sessed after increasing the number of cells examined.
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age of positive hTERC amplification cases in each group.
For statistical analysis, the row × column chi square
test (R × C Χ2) test (SPSS, Version 17) was used to com-
pare the positive rates between groups and the Wilcoxon
signed ranks test was used to compare continuous vari-
ables between groups.
Results
The association between the results of cytological test
(TCT) and pathological diagnosis
In the 40 control cases, TCT showed 3 cases of atypical
squamous epithelium of undetermined significance
(ASCUS), later shown on pathologic examination to be
inflammation. There was no low-grade squamous intrae-
pithelial lesion (LSIL), high-grade squamous intraepithe-
lial lesion (HSIL) or squamous cell carcinoma of the
cervix (SCC) (Table 1).
hTERC Amplification in control group and determination
of positive threshold
Among the normal cervical epithelial cells, there were
two red and two green signals in nucleus during cell
interphase. In the control group, on average 2.4% of spe-
cimens showed more than two red fluorescence signals
(hTERC amplification) on the whole slide (SD 1.2%), and
accordingly the positive threshold was set to 6.0%. The
incidence rate of positive hTERC amplification in the
control group was 0.0%.
The relationship between hTERC amplification in
exfoliated cervical epithelial cells and the pathological
diagnosis in the study group
hTERC amplification in heterogeneous cells demonstrated
more than two red signals and no less than two green sig-
nals in the nucleus during cell interphase. For the 81 CIN
cases, the hTERC amplification test showed that the
percentage of cells with more than two red signals was
13.5% (SD 12.4%), the incidence of positive case wasTable 1 TCT diagnosis of cervical epithelial cells in control an
Pathologic diagnosis Number NILM
Control group 40 37 (92.5)
Study group 151
CIN I 27 2 (7.4)
CIN II/III 54 0 (0.0)
Carcinoma in situ 17 0 (0.0)
Invasive Carcinoma 28 0 (0.0)
CIN LEEP post-treatment 11 7 (63.6)
Cervical cancer post-treatment 14 7 (50.0)
Results presented as number (%). TCT, thinprep cytologic test; Number, number of
squamous cells of undetermined significance; LSIL, low-grade squamous intraepithe
carcinoma; CIN, cervical intraepithelial neoplasia; LEEP, loop electrical excision proce71.6% (58/81), the sensitivity was 71.6% and the specificity
was 100%. As summarized in Table 2, the percentage of
hTERC amplification positive cells and the incidence of
positive case were 9.2% (SD 4.6%) and 44.4% (12/27) for
CIN I cases (the sensitivity was 44.4%), 16.0% (SD 14.4%),
85.1% (46/54) for CIN II to III cases (the sensitivity was
85.1%) 19.7% (SD 13.3%), 88.3% (15 /17) for carcinoma in
situ cases, 47.0% (SD 25.2%) and 100% (28/28) for invasive
carcinoma cases (the sensitivity was 100%) respectively.
The specificity was 100% for all these subgroups (Figure 1).
With the increase of pathological grade of the cervical
lesion, the percentage of exfoliated cells with more than
two red signals in the hTERC amplification test was also
elevated in the study group (except the cases with 2-year
post-treatment follow-up). The percentages of positive
cell in patients with CIN, carcinoma in situ and invasive
carcinoma were all statistically significantly higher than
in the control group (Table 2).
The relationship between hTERC amplification and TCT
among exfoliated cervical epithelial cells in the study
group
The rates of positive hTERC amplification among 4 types
of abnormal cervical epithelial cells (ASCUS, LSIL, HSIL
and SCC) were all significantly higher than among nor-
mal epithelial cells in the control group (P < 0.05). There
was no significant difference in the rate of positive
hTERC amplification between each type of abnormal
cells within the study group (P > 0.05). The percentages
of cells with positive hTERC amplification differed be-
tween various types of abnormal cells (P < 0.05), and
tended to be higher from ASCUS to SCC (Table 3).
Comparison of sensitivity between TCT and hTERC
amplification in the detection of cervical intraepithelial
lesions by FISH using pathological diagnosis as reference
In the study group, out of 27 CIN-I cases confirmed by
pathological examination, TCT detected 40.8% of LSIM
(11/27). Also, TCT identified 48.2% (26/54) of HSIL ind study groups
ASCUS LSIL HSIL SCC
3 (7.5) 0 (0.0) 0 (0.0) 0 (0.0)
7 (25.9) 11 (40.8) 7 (25.9) 0 (0.0)
7 (12.9) 21 (38.9) 26 (48.2) 0 (0.0)
4 (23.5) 2 (11.8) 11 (64.7) 0 (0.0)
0 (0.0) 0 (0.0) 0 (0.0) 28 (100.0)
4 (36.4) 0 (0.0) 0 (0.0) 0 (0.0)
7 (50.0) 0 (0.0) 0 (0.0) 0 (0.0)
cases; NILM, negative for intraepithelial lesion or malignancy; ASCUS, atypical
lial lesion; HSIL, high-grade squamous intraepithelial lesion; SCC, squamous cell
dure.
Table 2 hTERC amplification measured by FISH in
exfoliated cervical epithelial cells








40 2.4 ± 1.2 0 (0.0)
Study group 151
CIN I 27 9.2 ± 4.6* 44.4% (12 /27)*
CIN II/III 54 16.0 ± 14.4* 85.1% (46/54)*
Carcinoma
in situ
17 19.7 ± 13.3* 88.3% (15 /17)*
Invasive
Carcinoma








14 7.1 ± 2.0* 14.3% (2 /14)
FISH, fluorescence in situ hybridization; hTERC, human telomerase mRNA
component gene; Number, number of cases; CIN, cervical intraepithelial
neoplasia; LEEP, loop electrical excision procedure. *P < 0.05 (compared with
the control group).
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carcinoma in situ, and 100% (28/28) of SCC in cases
with cervical carcinoma. In contrast, the positive rate of
hTERC was 44.4% (12 /27) for CIN-I, 85.1% (46/54) forFigure 1 Photographs of hTERC amplification using FISH in the norm
Among the normal cervical epithelial cells, there were two red and two gr
amplification in heterogeneous cells was demonstrated as more than two
cell interphase. The hTERC amplification test showed that the percentage o
The hTERC amplification test showed that the percentage of cells with mo
The hTERC amplification test showed that the percentage of cells with mor
telomerase mRNA component gene; FISH, fluorescence in situ hybridizationCIN II to III, 88.3% (15/17) for carcinoma in situ and
100% (28/28) for cervical invasive carcinoma. The Χ2
test showed that FISH had higher sensitivity than TCT
in detecting all types of high-grade cervical intraepithe-
lial lesions (P < 0.05), except cervical invasive carcinoma.
For the 15 cases with 2-year post-treatment follow-up,
the results of TCT were NILM and ASCUS, consistent
with the negative findings of hTERC amplification.
hTERC amplification in exfoliated cervical cells at pre- and
post-operation among patients with normal 2-year
follow-up
The comparison of hTERC amplification in exfoliated cer-
vical or vaginal caecum cells at pre-operation and 2-year
post-operation in 25 patients, including 11 cases of CIN III
and 14 cases of cervical invasive carcinoma, with normal
follow-up, showed that after LEEP or radical hysterectomy
(using pathological diagnosis as the reference), both the
percentage of hTERC amplification-positive cells and rate
of positive cases decreased significantly (P < 0.05) (Table 4),
indicating that LEEP and radical surgery were able to sig-
nificantly reduce the number of cells with positive hTERC
amplification.
Discussion
HPV infection is a major risk factor for cervical cancer
[1,2,4]. About 95% of patients with CIN carry HPV onco-
genes, but only a few cases eventually develop invasive
cervical cancer. Therefore, HPV infection is not the onlyal cervix, CIN I, CIN III and cervical carcinoma. (A) Normal cervix.
een signals in nuclei during cell interphase. (B) CIN I. The hTERC
red signals and no less than two green signals in the nucleus during
f cells with more than two red signals was on average 9.2%. (C) CIN III.
re than two red signals was on average 16.0%. (D) Cervical cacinoma.
e than two red signals was on average 47.0%. hTERC, human
; CIN, cervical intraepithelial neoplasia.
Table 3 Relationship between TCT diagnosis and hTERC
amplification in exfoliated cervical epithelial cells
TCT
Diagnosis
Number Percentage of positive









NILM 16 3.2 ± 2.1 0 (0.0)
ASCUS 29 8.7 ± 6.3* 13 (44.8)*
LSIL 34 10.8 ± 4.8* 23 (67.6)*
HSIL 44 23.9 ± 15.0* 41 (93.2)*
SCC 28 31.07 ± 22.0* 28 (100)*
TCT, thinprep cytologic test; FISH, fluorescence in situ hybridization; hTERC,
human telomerase mRNA component gene; Number, number of cases; NILM,
negative for intraepithelial lesion or malignancy; ASCUS, atypical squamous
cells of undetermined significance; LSIL, low-grade squamous intraepithelial
lesion; HSIL, high-grade squamous intraepithelial lesion; SCC, squamous cell
carcinoma. *P <0.05(compared to the control group).
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also contribute to the development of cervical cancer [5].
Studies have found that during the transforming process
from atypical anomalies to cancer, almost all cervical epi-
thelial cells showed abnormal hTERC amplification
[6,8,17,18]. Human chromosome telomerase comprises
telomerase mRNA (hTERC), telomerase reverse tran-
scriptase (hTERT) and telomerase-binding protein (hTP1).
The mutation of hTERC could lead to functional change
of telomerase, which in turn causes chromosomal abnor-
malities [18,19]. Therefore, the detection of hTERC ampli-
fication could be regarded as a marker of high grade
lesion in future. After 1 to 3 years follow-up, patients with
CIN I/II and positive hTERC amplification were more
likely to progress to CIN III than those with negative
hTERC amplification, indicating that specific gene muta-
tion is the key for the development of CIN into invasive
carcinoma [8]. In fact, the fundamental differences be-
tween ASCUS, reversible mild CIN and progressive CIN
are the genetic characteristics. From CIN II/III to cervical
squamous cell carcinoma, the copy number of hTERC also
steadily increased [19].
This study showed that positive hTERC amplification
is not only an important biological marker for cervicalTable 4 The comparison of hTERC amplification at pre- and p
2-year follow-up
Pathologic Diagnosis N Percentage of positive cells (± SD%)
Pre-operation
CIN LEEP 11 11.2 ± 4.1
Radical hysterectomy 14 45.7 ± 21.6
hTERC, human telomerase mRNA component gene; CIN, cervical intraepithelial neop
operation).cancer [20-22], but also an important indicator of pre-
malignant CIN.
In the 40 control subjects, TCT showed 3 cases of
ASCUS, which were later confirmed on pathologic examin-
ation to be inflammation, and there were no LSIL, HSIL or
SCC cases. For the 81 CIN cases in the study group, the
hTERC amplification test showed that 13.5% (SD 12.4%) of
cells were positive (two red signals) , and the incidence rate
of positive case was 71.6% (58/81). Of them, the percentage
of positive cells and the incidence of positive cases were
9.2% (SD 4.6%) and 44.4% (12/27) for CIN I cases respect-
ively, and 16.0% (SD 14.4%), 85.1% (46/54) for CIN II to III
cases respectively. This suggested that the higher the patho-
logical grade of cervical lesion, the higher the likelihood of
being detected by hTERC amplification test in exfoliated
cervical cells. In this study, the rate of positive hTERC amp-
lification was 100% in patients with invasive cervical cancer.
Patients with CIN, carcinoma in situ and invasive carcin-
oma also had a higher percentage of positive cells than
control patients, and the differences were statistically sig-
nificant (P < 0.05). In addition, the percentage of positive
cells differed by pathological grade, and gradually increased
with increase in pathological grade within the study group.
Therefore, this method is important for CIN and cer-
vical cancer screening, especially for identifying pre-
malignant CIN. CIN with positive hTERC amplification,
regardless of the pathological grade, should be given spe-
cial attention in the clinical management.It should be
noted that in this study the comparison of hTERC amplifi-
cation results in the local exfoliated cells at pre-operation
and 2-year post-operation showed that after LEEP or rad-
ical hysterectomy, both the percentage of positive cells
and incidence of positive cases were significantly reduced,
indicating that LEEP and radical surgery might be able to
significantly reduce the number of cells with hTERC
amplification.
The significance of establishing criteria to determine
hTERC amplification
As for the issue of establishing positive criteria for
hTERC amplification, previous research defined that if the
percentage of cells with more than two red signals in nu-
clei during interphase reached 2.3%, the result was posi-
tive [8]. This criterion improved the detection rate of CIN,ost-operation among patients with normal
Incidence of positive cases (number incident cases/total)
Post-operation Pre-operation Post-operation
7.2 ± 2.7* 72.7% (8/11) 18.2%* (2/11)*
7.1 ± 2.0* 100% (14/14) 14.3%* (2 /14)
lasia; LEEP, loop electrical excision procedure. *P < 0.05 (compared with pre-
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and also increased the false positive rate.
Conclusion
The detection of genomic amplification of hTERC using
FISH is a non-invasive and effective approach for CIN. It is
not only an important biological marker for cervical cancer,
but also an important indicator of pre-malignant CIN.
Study limitation
This study was conducted in a single hospital, limited by
small number of cases and short duration of follow-up.
Further research is warranted to investigate other rele-
vant issues, for example whether positive hTERC ampli-
fication at 2-year follow-up after LEEP treatment among
CIN patients indicates the recurrence of CIN or progres-
sion to cervical cancer.
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